Quick answer (August 2026): Orforglipron (brand name Foundayo) is not yet available in Ireland. It is approved in the US (April 2026) and, as of 10 August 2026, in the UK — the first European country to authorise it — but it is still under review by the European Medicines Agency, so it has no EU licence, no Irish launch date and no Irish price. In the UK it is available privately — and Slimbr also has UK-registered doctors, so treatment through Slimbr is available in the UK. In its main trial, adults lost on average around 11–12% of their body weight over 72 weeks. The weight-loss medicines licensed and available in Ireland today are the injections Mounjaro (tirzepatide) and Wegovy (semaglutide), through a doctor-led provider such as Slimbr, from €229 for your first month.
For years, the most effective weight-loss medicines have all had one thing in common: a needle. Now there is a tablet. In April 2026 the US regulator approved orforglipron — sold there under the brand name Foundayo — the first GLP-1 weight-loss medicine you swallow once a day rather than inject. No fridge, no pen, no food rules.
Naturally, the first question we hear in Ireland is: can I get it? The honest answer right now is no — but it is worth understanding what orforglipron is, what the trials actually showed, and what a doctor in Ireland can already help you with today.
What is orforglipron (Foundayo)?
Orforglipron is a once-daily oral GLP-1 receptor agonist made by Eli Lilly. GLP-1 is the same family of gut hormone that medicines like Mounjaro (tirzepatide) and Wegovy (semaglutide) work on — they help reduce appetite and "food noise", so people tend to eat less without white-knuckle willpower.
The headline difference is the format. Most GLP-1 treatments are injections. There is already a GLP-1 tablet on the market (oral semaglutide, branded Rybelsus), but it is licensed for type 2 diabetes rather than weight loss — and it is a fussy one to take: it has to be swallowed on an empty stomach with a small sip of water, then nothing else for at least half an hour.
Orforglipron is a different kind of molecule — a small-molecule pill — so, according to Lilly, it can be taken at any time of day, with or without food or water. That convenience is the whole reason it has generated so much attention.
What did the trials show?
The main study, a Phase 3 trial called ATTAIN-1, enrolled 3,127 adults with obesity (without type 2 diabetes) and ran for 72 weeks. The results were presented at the EASD scientific meeting in 2025 and published in the New England Journal of Medicine.
On the highest dose, participants lost on average around 11–12% of their body weight over those ~72 weeks, compared with about 2% on placebo. It is important to read that as a trial average rather than a promise — individual results vary a great deal, and these figures come from a controlled study alongside diet and exercise support.
For context, on the trial numbers that puts orforglipron a little below injectable semaglutide and further below tirzepatide, which has shown larger average losses in its own studies. In other words, the pill's appeal is convenience and format — not a bigger result than what is already available.
What about side effects?
In the trials, the most common side effects were gastrointestinal — nausea, vomiting, diarrhoea and constipation — and they were mostly mild to moderate, occurring mainly while the dose was being increased. A minority of people stopped treatment because of side effects, and the rate rose at higher doses. As with all GLP-1 medicines, the US label also carries the class warning about a rare risk relating to thyroid tumours seen in animal studies.
None of this is medical advice — it is simply what the published research reported. Whether any GLP-1 medicine is appropriate for a given person is a clinical decision made with a doctor, which is exactly why medical supervision matters with these treatments.
Can you get Foundayo (orforglipron) in Ireland yet?
Not yet. Orforglipron's April 2026 approval was granted by the US Food and Drug Administration, and a US approval does not make a medicine available in Ireland. In Europe, the UK became the first country to authorise it (10 August 2026, as Foundayo), but in the EU orforglipron is still under review by the European Medicines Agency, and it has not been licensed for Ireland.
Industry commentary generally points to an Irish or wider European launch no earlier than around 2027 — but that is an estimate, not a confirmed date, and timelines for new medicines often shift. So if you have seen the "weight-loss pill approved" headlines and wondered whether you can pick it up here, the realistic picture is: it is coming, but it is not here, and no clinic in Ireland can legitimately prescribe Foundayo today.
In the UK: approved — and Slimbr's UK-registered doctors can advise
On 10 August 2026 the UK's MHRA authorised orforglipron (Foundayo) for weight management and type 2 diabetes — making the UK the first country in Europe to approve it. It is available privately on prescription (not on the NHS), and early supply is limited while the launch ramps up.
Slimbr also has UK-registered doctors, and treatment through Slimbr is available in the UK — so for people in the UK, Foundayo can be discussed with the doctor today where it's clinically appropriate. In Ireland the position hasn't changed yet: not available, with licensed injectable options as today's doctor-led route.
Did you know you can claim up to 75% back on your health insurance?
See how the claim works →What you can do in Ireland today
While the pill works its way through European approval, the established options for medical weight loss in Ireland are the injectable GLP-1 treatments — Mounjaro (tirzepatide) and Wegovy (semaglutide) — both available here on private prescription through doctor-led services. They are not currently reimbursed by the HSE for weight management, so they are paid privately.
On the trial evidence, today's injectables actually show larger average weight loss than orforglipron's numbers, so waiting for a pill is not necessarily the "better" route — it depends on what matters to you, whether that is the format, the evidence, or the cost. A proper service starts with a clinician checking that treatment is suitable and safe for you, rather than simply selling a product. That is the difference a doctor-led clinic makes, and you can read more about access and cost in our complete Mounjaro in Ireland guide.
Orforglipron and today's GLP-1 options in Ireland — at a glance
| Orforglipron (Foundayo) | Injectable GLP-1s (Mounjaro, Wegovy) | Rybelsus (oral semaglutide) | |
|---|---|---|---|
| Type of medicine | Small-molecule GLP-1 pill, taken once a day | Injectable treatments (Mounjaro, Wegovy) | A GLP-1 tablet (oral semaglutide) |
| Food and water rules | None, according to Eli Lilly — any time of day, with or without food | Not applicable | Must be taken on an empty stomach with a small sip of water |
| Licensed for | Weight management — approved in the US (April 2026) and the UK (August 2026); not yet in the EU | Weight management | Type 2 diabetes — not weight loss |
| What the trials reported | An average of around 11–12% body-weight loss over ~72 weeks on the highest dose (ATTAIN-1) — a trial average, not a promise | Larger average losses in their own trials | Studied in type 2 diabetes rather than weight management |
| Available in Ireland today? | No — still under EMA review; commentary points to around 2027 at the earliest | Yes — on private prescription through doctor-led services | Licensed for type 2 diabetes only — not a weight-loss option |
Accurate at the time of writing (July 2026). Trial figures are averages from controlled studies alongside diet and lifestyle support — individual results vary, and whether any GLP-1 medicine is appropriate is a clinical decision made with a doctor.
Frequently asked questions
Is Foundayo (orforglipron) available in Ireland?
No. Orforglipron is approved in the US (April 2026) and the UK (10 August 2026), but it is still under review by the European Medicines Agency and has not been licensed in Ireland, so it cannot be prescribed here yet. A European launch is widely estimated to be no earlier than around 2027, but no date is confirmed.
What is orforglipron?
Orforglipron is a once-daily oral GLP-1 receptor agonist developed by Eli Lilly, sold as Foundayo in the US and UK. Unlike the existing GLP-1 tablet (oral semaglutide), it can be taken at any time of day without food or water restrictions, and unlike Mounjaro or Wegovy it is swallowed rather than injected.
How much weight did people lose on orforglipron?
In its main 72-week Phase 3 trial, people on the highest dose lost on average around 11–12% of their body weight, versus about 2% on placebo. That is a trial average alongside diet and exercise — individual results vary, and it is not a guaranteed outcome.
Orforglipron vs Mounjaro — which is better?
They target the same GLP-1 system, but on the published trial figures Mounjaro (tirzepatide) has shown larger average weight loss than orforglipron. Orforglipron's advantage is being a daily pill with no food rules. The right choice is individual and is best decided with a doctor — and for now, only the injectables are actually available in Ireland.
Is there a weight-loss pill I can get in Ireland now?
Not a small-molecule pill like orforglipron. The medical weight-loss treatments available in Ireland today are injectable GLP-1s such as Mounjaro and Wegovy, prescribed privately through doctor-led services after a clinical assessment.
